GlassScriptPhysician profile
Marissa B Curry
NPI 1225259666
$1,239.49
in general payments reported to CMS, 2019-2025
18 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.16 · 2020: $172 · 2021: $104 · 2022: $180 · 2023: $313 · 2024: $278 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $278.96 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $214.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $154.77 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $101.50 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $80.60 | 2021-2023 | Ubrelvy |
| Exact Sciences Corporation | $54.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $50.46 | 2022 | |
| Pfizer INC. | $49.17 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $44.22 | 2024-2025 | Voquezna |
| Hologic Sales and Service, LLC | $41.38 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $32.29 | 2020-2023 | Farxiga |
| Edwards Lifesciences Corporation | $25.13 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biogen, INC. | $24.50 | 2025 | Spinraza |
| Takeda Pharmaceuticals U.S.A., INC. | $22.16 | 2020 | |
| Arbor Pharmaceuticals, INC. | $19.96 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $16.17 | 2019 | |
| Astellas Pharma US INC | $15.27 | 2023 | Myrbetriq |
| Dexcom, INC. | $14.13 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.